## Background: The accumulation of chromogranin a (chr a) and cathepsin d (cath d) gene products may be important in prostate carcinoma progression. this study assessed whether the levels of immunoreactivity for chr a and cath d are better predictors of disease specific survival than conventional p
Prostate carcinoma and long term survival
โ Scribed by Jan Adolfsson; Lars-Erik Rutqvist; Gunnar Steineck
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 111 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
The long term survival of patients with prostate carcinoma is not well understood. the objective of the current study was to investigate the temporal trend of prostate carcinoma mortality in patients who survived > or = 10 years after diagnosis.
Methods:
Men with prostate carcinoma diagnosed from 1958 through 1983 in the stockholm/gotland region in sweden and who survived > or = 10 years after the diagnosis were investigated regarding survival beyond 10 years. the expected survival was calculated from an annually selected age and time-matched cohort of men from the general population in the same geographic region. the relative survival was expressed as the annual quotient of the observed survival over the expected survival.
Results:
The authors identified 1896 patients who had survived > or = 10 years. the relative survival decreased up to approximately 18 years after the diagnosis, whereupon it reached a plateau that was constant up to 30 years after diagnosis.
Conclusions:
Men with prostate carcinoma surviving > or = 10 years have an excess mortality compared with age-matched controls. this excess mortality ceases 20 to 23 years after diagnosis and the observed and the expected survival are similar, indicating few, if any, deaths from prostate carcinoma from there on.
๐ SIMILAR VOLUMES
## Background: Survival of patients with stage iv (based on general rules established by the japanese research society for gastric cancer) gastric carcinoma often is unfavorable. among patients with a poor prognosis, a few do survive > 5 years. the authors examined pathologic and biologic features